Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish ...

Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford the $1, ...

(Reuters) -Eli Lilly said on Tuesday it cut the price for ... of thousands of doses of copies of Lilly's Zepbound and Novo's Wegovy while the medicines were in shortage are running out of time ...

INDIANAPOLIS — Eli Lilly announced Wednesday the launch of higher doses of Zepbound — and that the company is lowering the price of certain doses. People taking Zepbound, or interested in starting, ...

Eli Lilly is growing faster with Zepbound and Mounjaro ... Novo Nordisk also cut profits in the second quarter due to weaker Wegovy sales and rebates and it missed revenue estimates in the ...

Eli Lilly (LLY) is making more doses of its blockbuster ... along with Novo Nordisk’s rival drug Wegovy, from its drug shortage list. Typically, the Food, Drug, and Cosmetic Act prohibits ...

Eli Lilly began offering vials of the two lowest ... pharmacies charge on average for their versions of Zepbound and Wegovy in the U.S. Hims & Hers forecast sales of $725 million from its weight ...

Eli Lilly is expanding the supply and cutting the ... Semaglutide, which is the active ingredient in Novo Nordisk's Wegovy and Ozempic, as well as tirzepatide, are considered GLP-1 drugs.

In August, drug manufacturer Eli Lilly began sending cease-and-desist ... compounded drug that is essentially a copy of Ozempic or Wegovy is illegal.” The company has already filed more than ...